FR2647017A1 - Agent antitumoral et agent antimetastatique contenant un inhibiteur de la ribonuclease comme composant actif - Google Patents
Agent antitumoral et agent antimetastatique contenant un inhibiteur de la ribonuclease comme composant actif Download PDFInfo
- Publication number
- FR2647017A1 FR2647017A1 FR8914226A FR8914226A FR2647017A1 FR 2647017 A1 FR2647017 A1 FR 2647017A1 FR 8914226 A FR8914226 A FR 8914226A FR 8914226 A FR8914226 A FR 8914226A FR 2647017 A1 FR2647017 A1 FR 2647017A1
- Authority
- FR
- France
- Prior art keywords
- tumor
- day
- ribonuclease inhibitor
- mouse
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100037968 Ribonuclease inhibitor Human genes 0.000 claims abstract description 68
- 101710141795 Ribonuclease inhibitor Proteins 0.000 claims abstract description 67
- 229940122208 Ribonuclease inhibitor Drugs 0.000 claims abstract description 67
- 239000003161 ribonuclease inhibitor Substances 0.000 claims abstract description 67
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 22
- 239000002257 antimetastatic agent Substances 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 71
- 210000004881 tumor cell Anatomy 0.000 claims description 33
- 206010027476 Metastases Diseases 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 26
- 230000009401 metastasis Effects 0.000 claims description 21
- 210000004072 lung Anatomy 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 230000000259 anti-tumor effect Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 12
- 210000001165 lymph node Anatomy 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 102000006382 Ribonucleases Human genes 0.000 claims description 8
- 108010083644 Ribonucleases Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 210000002429 large intestine Anatomy 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 51
- 230000000694 effects Effects 0.000 description 48
- 230000005764 inhibitory process Effects 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 18
- 238000007912 intraperitoneal administration Methods 0.000 description 14
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 12
- 229960001420 nimustine Drugs 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 9
- 230000003327 cancerostatic effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 208000029742 colonic neoplasm Diseases 0.000 description 8
- 229960003290 cortisone acetate Drugs 0.000 description 8
- 229960002949 fluorouracil Drugs 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000002601 intratumoral effect Effects 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 102100035695 Gamma-aminobutyric acid receptor-associated protein Human genes 0.000 description 6
- 101001001372 Homo sapiens Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000037841 lung tumor Diseases 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 102100022987 Angiogenin Human genes 0.000 description 3
- 229930192392 Mitomycin Natural products 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001919 adrenal effect Effects 0.000 description 3
- 108010072788 angiogenin Proteins 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000035777 life prolongation Effects 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000027950 fever generation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229940115286 lentinan Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001165766 Tetraoninae Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108010024226 placental ribonuclease inhibitor Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
- Y10S530/851—Placenta; amniotic fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1126387A JP2842888B2 (ja) | 1989-05-19 | 1989-05-19 | リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2647017A1 true FR2647017A1 (fr) | 1990-11-23 |
| FR2647017B1 FR2647017B1 (enExample) | 1994-08-19 |
Family
ID=14933885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8914226A Granted FR2647017A1 (fr) | 1989-05-19 | 1989-10-30 | Agent antitumoral et agent antimetastatique contenant un inhibiteur de la ribonuclease comme composant actif |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5175005A (enExample) |
| JP (1) | JP2842888B2 (enExample) |
| DE (1) | DE3935132A1 (enExample) |
| FR (1) | FR2647017A1 (enExample) |
| GB (1) | GB2231793B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5529775A (en) * | 1988-04-06 | 1996-06-25 | Alfacell Corporation | Compositions comprising ONCONASE(™) and cisplatin, melphalan, or doxorubicin HCl |
| DK1156043T3 (da) * | 1992-07-24 | 2004-03-01 | Univ California | Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0291686B1 (en) * | 1987-04-14 | 1993-10-13 | The President And Fellows Of Harvard College | Inhibitors of angiogenin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4552888A (en) * | 1982-01-15 | 1985-11-12 | Eli Lilly And Company | Ascorbic acid ethers in angiogene |
| US4599331A (en) * | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| US5019556A (en) * | 1987-04-14 | 1991-05-28 | President And Fellows Of Harvard College | Inhibitors of angiogenin |
| US4966964A (en) * | 1987-04-14 | 1990-10-30 | President And Fellows Of Harvard College | Inhibitors of angiogenin |
-
1989
- 1989-05-19 JP JP1126387A patent/JP2842888B2/ja not_active Expired - Fee Related
- 1989-10-02 US US07/416,066 patent/US5175005A/en not_active Expired - Fee Related
- 1989-10-18 DE DE3935132A patent/DE3935132A1/de not_active Withdrawn
- 1989-10-30 FR FR8914226A patent/FR2647017A1/fr active Granted
- 1989-10-31 GB GB8924450A patent/GB2231793B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0291686B1 (en) * | 1987-04-14 | 1993-10-13 | The President And Fellows Of Harvard College | Inhibitors of angiogenin |
Non-Patent Citations (2)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 109, no. 21, 21 novembre 1988, page 282, résumé no. 185714w, Columbus, Ohio, US; J.F. RIORDAN et al.: "Human angiogenin, an organogenic protein", & BR. J. CANCER 1988, 57(6), 587-90 * |
| PROC. NATL. ACAD. SCI. USA, vol. 84, avril 1987, pages 2238-2241, Washington, US; R. SHAPIRO et al.: "Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin" * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2231793B (en) | 1993-10-06 |
| JPH02306922A (ja) | 1990-12-20 |
| DE3935132A1 (de) | 1990-11-22 |
| JP2842888B2 (ja) | 1999-01-06 |
| FR2647017B1 (enExample) | 1994-08-19 |
| GB8924450D0 (en) | 1989-12-20 |
| GB2231793A (en) | 1990-11-28 |
| US5175005A (en) | 1992-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dusting | Nitric oxide in cardiovascular disorders | |
| BE1005018A3 (fr) | Medicaments qui contiennent, comme substance active, des acides carboxyliques contenant du soufre, ainsi que leur utilisation pour lutter contre des retrovirus. | |
| US5457130A (en) | Eicosapentaenoic acid used to treat cachexia | |
| AU643201B2 (en) | Use of eicosapentaenoic acid for the treatment of cachexia | |
| JPH04505752A (ja) | オリゴヌクレオチドを使用する癌治療用の方法及び組成物 | |
| JPH11507083A (ja) | ポルフィリンによる移植片生存の延長 | |
| JP2023533485A (ja) | 重症型の肺高血圧症の治療方法 | |
| DE3812605A1 (de) | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes | |
| EP0080401A1 (fr) | Nouveaux médicaments anticancéreux pour le traitement des leucémies T constitués de la chaine A de la ricine et d'un anticorps monoclonal spécifique | |
| EP2173349A2 (fr) | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan | |
| EP3703718A1 (fr) | Formulation liposomale de lipopolysaccharide bactérien combinée à un agent cytotoxique, et son utilisation en therapie anti-tumorale | |
| WO2021084166A1 (fr) | Nanostructure d'or comprenant des enzymes et des agents antioxydants | |
| EP0542630A2 (fr) | Utilisation de dérivés d'amphotéricine B, comme inhibiteurs de protéases | |
| EP4061398A1 (fr) | Extrait liquide aqueux de spiruline pour la prévention et/ou le traitement des neuropathies périphériques chimio-induites et leurs symptômes, composition et utilisation correspondantes | |
| FR2550944A1 (fr) | Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers | |
| FR2647017A1 (fr) | Agent antitumoral et agent antimetastatique contenant un inhibiteur de la ribonuclease comme composant actif | |
| EP0579791A1 (fr) | Composition cellulaire pour le traitement des organismes humains ou animaux | |
| EP0352146A1 (fr) | Régulateur biologique extrait de Gingko Biloba, actif dans diverses pathologies. | |
| CN117982658A (zh) | Enpp1抑制剂和胞外核苷酸酶抑制剂在协同抑制肿瘤中的应用 | |
| EP0306377B1 (fr) | Nouvelles compositions d'éléments minéraux et/ou oligoéléments et leur procédé de préparation | |
| JPH08510131A (ja) | 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用 | |
| EP0086152B1 (fr) | Médicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent | |
| JP3199081B2 (ja) | 抗腫瘍剤 | |
| EP1483374A2 (fr) | Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro | |
| WO2001072327A2 (fr) | Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| ST | Notification of lapse |